LivaNova (NASDAQ:LIVN - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 3.300-3.400 for the period, compared to the consensus EPS estimate of 3.160. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.
LivaNova Price Performance
Shares of LivaNova stock traded down $0.69 during trading on Wednesday, hitting $52.28. 1,250,752 shares of the stock traded hands, compared to its average volume of 620,685. The firm's fifty day moving average is $50.83 and its 200-day moving average is $53.16. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of -88.28 and a beta of 1.00. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.47. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49.
LivaNova (NASDAQ:LIVN - Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.15. The company had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. Research analysts expect that LivaNova will post 2.58 EPS for the current fiscal year.
Analysts Set New Price Targets
LIVN has been the subject of several research reports. Robert W. Baird raised LivaNova from a "neutral" rating to an "outperform" rating and increased their target price for the stock from $55.00 to $66.00 in a research report on Tuesday, September 17th. The Goldman Sachs Group assumed coverage on LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 target price for the company. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Needham & Company LLC boosted their price target on LivaNova from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, July 31st. Finally, Stifel Nicolaus raised their target price on LivaNova from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $69.83.
Get Our Latest Stock Analysis on LivaNova
LivaNova Company Profile
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
